
CLAIMS

1. A compound having the formula:



(II)

wherein,

L^2 is substituted or unsubstituted C_1-C_{10} alkylene; and

y is an integer from 0 to 3;

z is an integer from 0 to 5;

X is -N=, -CH= or -CR^5=;

R^1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R^3, R^4 and R^5 are independently -CN, -$S(O)_nR^6$, -NR^7R^8, -$C(O)R^9$, -NR^{10}-$C(O)R^{11}$, -NR^{12}-C(O)-OR^{13}, -$C(O)NR^{14}R^{15}$, -$NR^{16}S(O)_2R^{17}$, -OR^{18}, -$S(O)_2N(R^{19})_2$, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein n is an integer from 0 to 2, wherein if z is greater than 1, two R^3 moieties are optionally joined together to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and

R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18} and R^{19} are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

or a racemate, diastereomer, tautomer, or a geometric isomer thereof, or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein L^2 is methylene.

3. The compound of claim 1, wherein X is -N= or -CH=.

4. The compound of claim 1, wherein R^1 is hydrogen.

5. The compound of claim 1, wherein z is 2 and two R^3 moieties at adjacent vertices are joined together to form a substituted or unsubstituted heterocycloalkyl.

6. The compound of claim 1, wherein R^3 is $-OR^{18}$, and R^{18} is hydrogen or unsubstituted C_1-C_{10} alkyl.

7. The compound of claim 1, wherein


L^2 is methylene;


X is -N= or -CH=;


R^1 is hydrogen; and

y and z are 0.

8. The compound of claim 1 having the formula:


,


, or


.

9. A composition comprising a population of isolated cells and an amount of a compound according to claim 1 sufficient to improve survival of isolated cells by at least 2 fold compared to the absence of the compound.

10. The composition of claim 9, wherein the cells are selected from the group consisting of stem cells, induced stem cells, pluripotent stem cells, progenitor cells, differentiated cells, beta cells, and fibroblasts.

11. The compound of claim 1, wherein

L^2 is unsubstituted C_{1-6} alkylene;

y is an integer from 0 to 1;

z is an integer from 0 to 2;

X is -N=, or -CH=;







R^1 is hydrogen, or unsubstituted C_{1-6} alkyl;






R^3 is $-C(O)NR^{14}R^{15}$, $-OR^{18}$, or substituted or unsubstituted C_{1-6} alkyl, wherein the substituted C_{1-6} alkyl is substituted with halogen, wherein if z is 2, two R^3 moieties are joined together to form an unsubstituted C_{3-8} heterocycloalkyl;

R^4 is $-OR^{18}$; and


R^{14}, R^{15}, and R^{18} are independently hydrogen, or unsubstituted C_{1-6} alkyl.

12. The compound of claim 1 having the formula selected from the group consisting of:


,

,

,

,

,

,



,

,

,

,
and

.

13. The compound of claim 1 having the formula:


.

CLAIMS

1. A compound having the formula:



(II)

wherein,

L^2 is substituted or unsubstituted C_1-C_{10} alkylene; and

y is an integer from 0 to 3;

z is an integer from 0 to 5;

X is -N=, -CH= or -CR^5=;

R^1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R^3, R^4 and R^5 are independently -CN, -$S(O)_nR^6$, -NR^7R^8, -$C(O)R^9$, -NR^{10}-$C(O)R^{11}$, -NR^{12}-C(O)-OR^{13}, -$C(O)NR^{14}R^{15}$, -$NR^{16}S(O)_2R^{17}$, -OR^{18}, -$S(O)_2N(R^{19})_2$, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein n is an integer from 0 to 2, wherein if z is greater than 1, two R^3 moieties are optionally joined together to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and

R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18} and R^{19} are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

or a racemate, diastereomer, tautomer, or a geometric isomer thereof, or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein L^2 is methylene.

3. The compound of claim 1, wherein X is -N= or -CH=.

4. The compound of claim 1, wherein R^1 is hydrogen.

5. The compound of claim 1, wherein z is 2 and two R^3 moieties at adjacent vertices are joined together to form a substituted or unsubstituted heterocycloalkyl.

6. The compound of claim 1, wherein R^3 is $-OR^{18}$, and R^{18} is hydrogen or unsubstituted C_1-C_{10} alkyl.

7. The compound of claim 1, wherein


L^2 is methylene;

X is -N= or -CH=;


R^1 is hydrogen; and

y and z are 0.


8. The compound of claim 1 having the formula:



,



, or



or a racemate, diastereomer, tautomer, or a geometric isomer thereof, or a pharmaceutically acceptable salt thereof.

9. A composition comprising a population of isolated cells and an amount of a compound according to claim 1 sufficient to improve survival of isolated cells by at least 2 fold compared to the absence of the compound.

10. The composition of claim 9, wherein the cells are selected from the group consisting of stem cells, induced stem cells, pluripotent stem cells, progenitor cells, differentiated cells, beta cells, and fibroblasts.

11. The compound of claim 1, wherein

L^2 is unsubstituted C_{1-6} alkylene;

y is an integer from 0 to 1;

z is an integer from 0 to 2;

X is -N=, or -CH=;





R^1 is hydrogen, or unsubstituted C_{1-6} alkyl;








R^3 is $-C(O)NR^{14}R^{15}$, $-OR^{18}$, or substituted or unsubstituted C_{1-6} alkyl, wherein the substituted C_{1-6} alkyl is substituted with halogen, wherein if z is 2, two R^3 moieties are joined together to form an unsubstituted C_{3-8} heterocycloalkyl;

R^4 is $-OR^{18}$; and

R^{14}, R^{15}, and R^{18} are independently hydrogen, or unsubstituted C_{1-6} alkyl.


12. The compound of claim 1 having the formula selected from the group consisting of:


,

,

,

,


,

,

,

,

,

,
and



or a racemate, diastereomer, tautomer, or a geometric isomer thereof, or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 having the formula:



or a racemate, diastereomer, tautomer, or a geometric isomer thereof, or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1 having the formula:


.